Last reviewed · How we verify
eye drops (Tropicamid)
Tropicamide is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation.
Tropicamide is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation. Used for Mydriasis and cycloplegia for diagnostic ophthalmologic examination, Pupil dilation for fundoscopic examination.
At a glance
| Generic name | eye drops (Tropicamid) |
|---|---|
| Also known as | Agepha |
| Sponsor | Medical University of Graz |
| Drug class | Anticholinergic agent / Mydriatic |
| Target | Muscarinic acetylcholine receptors (M1, M3) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Tropicamide competitively antagonizes acetylcholine at muscarinic receptors on the iris sphincter muscle and ciliary muscle. This causes mydriasis (pupil dilation) and cycloplegia (paralysis of accommodation), allowing clear visualization of the retina during ophthalmologic examination. The effect is temporary and reversible.
Approved indications
- Mydriasis and cycloplegia for diagnostic ophthalmologic examination
- Pupil dilation for fundoscopic examination
Common side effects
- Transient stinging or irritation
- Blurred vision
- Photophobia
- Increased intraocular pressure (in susceptible patients)
- Systemic anticholinergic effects (rare with topical use)
Key clinical trials
- Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients (NA)
- The Effect Of Polycystic Ovarian Syndrome Treatment On Ocular Surface.
- Chromosome 18 Clinical Research Center
- Adaptive Optics (AO) Analysis of Retinal Arteries in Patients With Recent Stroke (STROKAO)
- Subthreshold Micropulse Laser Therapy (SML) in Retinitis Pigmentosa (NA)
- Pharmacodynamics of a Fixed Dose Combination of 0.34% Tropicamide and 2.5% Phenylephrine Hydrochloride, Eye Drop, Solution (PHASE1, PHASE2)
- Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's Disease
- Evaluation of Pupil Dilation Speed With the MAP Dispenser (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- eye drops (Tropicamid) CI brief — competitive landscape report
- eye drops (Tropicamid) updates RSS · CI watch RSS
- Medical University of Graz portfolio CI